Literature DB >> 24708212

Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS.

Mei-hua Bao1, Yi-wen Zhang, Xiao-ya Lou, Yan Xiao, Yu Cheng, Hong-hao Zhou.   

Abstract

Oxidized low density lipoprotein (oxLDL) induced injury of endothelial cells is considered to be the first step in the pathogenesis of atherosclerosis. This study aimed to investigate some of the effects and mechanisms of puerarin on oxLDL-induced endothelial injuries. We measured cell viability, and the release of lactate dehydrogenase (LDH), nitric oxide (NO), and interleukin-8 (IL-8) to evaluate the protective effects of puerarin. Intracellular reactive oxygen species (ROS) were detected using 2',7'-dichlorofluorescein diacetate (DCFH-DA). The expression of lectin-like low-density lipoprotein receptor-1 (LOX-1), endothelial nitric oxide synthase (eNOS), cyclooxygenase 2 (COX-2), p38MAPK, and protein kinase B (PKB) phosphorylation, nuclear factor-κB (NF-κB) nuclear translocation, and inhibitor of κB (IκB) degradation were detected using quantitative real-time PCR or Western blot. The results showed that oxLDL significantly decreased cell viability, increased LDH and IL-8 release, inhibited NO production, and induced COX-2 expression. Pretreatment with puerarin led to a strong inhibition of these effects. OxLDL stimulated the expression of LOX-1, the overproduction of ROS, the phosphorylation of p38MAPK, the dephosphorylation of PKB, activation of NF-κB, and the degradation of IκB. These oxLDL-induced effects were suppressed after puerarin pretreatment. These results suggest that puerarin inhibits oxLDL-induced endothelial cell injuries, at least in part, via inhibition of the LOX-1-mediated p38MAPK-NF-κB inflammatory and the PKB-eNOS signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24708212     DOI: 10.1139/cjpp-2013-0322

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  5 in total

Review 1.  Roles of eNOS in atherosclerosis treatment.

Authors:  Fen-Fang Hong; Xiao-Yu Liang; Wei Liu; Sha Lv; Shu-Jin He; Hai-Bin Kuang; Shu-Long Yang
Journal:  Inflamm Res       Date:  2019-04-01       Impact factor: 4.575

2.  Pinoresinol Diglucoside Alleviates oxLDL-Induced Dysfunction in Human Umbilical Vein Endothelial Cells.

Authors:  Jinpeng Yao; Zhipeng Zou; Xiangfen Wang; Xiaoping Ji; Jun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-30       Impact factor: 2.629

Review 3.  Effects of puerarin on chronic inflammation: Focus on the heart, brain, and arteries.

Authors:  Li Zhang; Lisheng Liu; Mingyi Wang
Journal:  Aging Med (Milton)       Date:  2021-12-15

4.  Puerarin Inhibits oxLDL-Induced Macrophage Activation and Foam Cell Formation in Human THP1 Macrophage.

Authors:  Heng Zhang; Zhenhua Zhai; Hongyu Zhou; Yao Li; Xiaojie Li; Yuhan Lin; Weihong Li; Yueping Shi; Ming-Sheng Zhou
Journal:  Biomed Res Int       Date:  2015-10-21       Impact factor: 3.411

5.  Puerarin inhibits vascular smooth muscle cells proliferation induced by fine particulate matter via suppressing of the p38 MAPK signaling pathway.

Authors:  Qiang Wan; Zhongyong Liu; Yuping Yang
Journal:  BMC Complement Altern Med       Date:  2018-05-04       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.